Figure 3.
Biological activity of MAGE-A3 TCR engineered T cells in patient PBMC. A. PBMC samples from patients 1–8 were obtained approximately one month post-infusion and co-cultured with control tumor line H1299 (MAGE-A3+/HLA-A*0201−) or reactive tumor line H1299-A2 (MAGE-A3+/HLA-A*0201+). Shown are the resultant FACS density plots gated on CD3+/mouse-TCR beta+ for effector cytokines IFN-γ and TNF. The percentages of positive cells were as indicated in each quadrant. B. PBMC samples from patients 1–9 were obtained approximately one month post-infusion and subject to Elispot analysis. Number of Elispot reactive cells are plotted following PBMC co-culture with MAGE-A3-peptide pulsed cells (left side) or MAGE-A3+/HLA-A*0201+ tumor cell line (right side). Results from control peptide pulsed cells and MAGE-A3+/HLA-A*0201− tumor cell lines were <10 spots/1 × 105 PBMC (not shown).